IL22 and inflammatory bowel disease: However, CG-598 treatment induced the production of IL-10 and IL-22 from lamina propria CD4+ T-cells suggesting that strengthening HIF-1α induction in T-cells at sites of inflammation might be a therapeutic strategy for IBD management.